

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

Thursday, 9 October 2025

13:00 – 14:00

### Session I: Pathogenesis of acquired AA

**Chairs:** Edward Gordon-Smith (UK) & Andrea Bacigalupo (IT)

13:00 – 13:20

From a genetic point of view

13:20 – 13:40

From an immunology point of view

13:40 – 14:00

HLA and AA: Friends or Foe

Marcin Wlodarski (DE)

Leo Hansmann (DE)

Shinji Nakao (JP)

14:00 – 15:30

### Session II: 30 years in AA – What have we learned

**Chairs:** Austin Kulasekararaj (UK) & Antonio Risitano (IT)

14:00 – 14:20

Diagnosis

14:20 – 14:40

Treatment I: Transplantation

14:40 – 15:00

Treatment II: IST

15:00 – 15:20

Long-term outcome and late effects

15:20 – 15:30

Discussion: What have learned in 30 years

Alicia Rovó (CH)

Andrea Bacigalupo (IT)

Jakob Passweg (CH)

André Tichelli (CH)

15:30 – 16:00

### Coffee Break

16:00 – 16:45

### Industry Symposium kindly sponsored by Alexion:

#### Scaling New Heights in PNH: Navigating the Path of Dual Complement Inhibition

**Chair:** Austin Kulasekararaj (UK)

16:00 – 16:03

Introduction, welcome, faculty introduction and agenda overview

16:03 – 16:18

Terminal Complement Inhibition in PNH: A Foundation for Disease Control

16:18 – 16:32

The Next Step in Complement Control: Addressing Extravascular Haemolysis in PNH

16:32 – 16:40

Panel Discussion/Q&A

16:40 – 16:45

Key Takeaways and Closing Remarks

Talha Munir (UK)

Talha Munir (UK)

Austin Kulasekararaj (UK)

All

Austin Kulasekararaj (UK)

16:45 – 17:30

### Session III: Inherited BMFs: HCT Versus gene therapy

**Chairs:** Carlo Dufour (IT) & Constantijn Halkes (NL)

16:45 – 17:10

Role of HCT in inherited BMFs

17:10 – 17:30

Genetic counselling of families (patients and donor!) with inherited BMFs

Éliane Gluckman (FR)

Fabian Beier (DE)

20:00 – 22:00

### Scientific Business Meeting

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

### Friday, 10 October 2025

09:00 – 10:00	<b>Session IV: Complement</b> <b>Chairs:</b> <i>Camilla Frieri (IT) &amp; Jaroslaw Maciejewski (US)</i>	
09:00 – 09:20	Complement and disease	Daniel Ricklin (CH)
09:20 – 09:40	Other complement – associated diseases / Benefits of complement inhibitors in other indications	Patricia Hirt-Minkowski (CH)
09:40 – 10:00	Discussion: complement and transplant/more	
10:00 – 11:00	<b>Session V: Daily hurdles in AA</b> <b>Chairs:</b> <i>Olivia Naveiras (CH) &amp; Austin Kulasekararaj (UK)</i>	
10:00 – 10:20	Tapering EPAG – How, when and when to re-start again...	Beatrice Drexler (CH)
10:20 – 10:40	Work up and treatment of MAA	Britta Höchsmann (DE)
10:40 – 11:00	How to distinguish “clonal haematopoiesis” from “transformation” in AA	Daria Babushok (US)
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 12:45	<b>Session VI: Initiative session</b> <b>Chairs:</b> <i>Jakob Passweg (CH) &amp; Andrea Bacigalupo (IT)</i>	
11:30 – 11:55	ICARIIS initiative	Régis Peffault de la Tour (FR)
11:55 – 12:20	AA treatment decisions/algorithm	Rodrigo Calado (BR)
12:20 – 12:45	Status of art: HCT versus IST (SAAWP initiatives)	Austin Kulasekararaj (UK) Antonio Risitano (IT)
12:45 – 13:30	<b>Lunch Break</b>	
13:30 – 14:15	<b>Industry Symposium kindly sponsored by Novartis:</b> <b>Bone Marrow Failure and Complement Dysregulation: Managing Overlapping AA and PNH</b> <b>Chair:</b> <i>Beatrice Drexler (CH)</i>	
<i>This symposium is organized and funded by Novartis and is intended for an audience of non-US HCPs within the context of the EBMT Severe Aplastic Anaemia Working Party Educational Course 2025 on 9-11 October 2025, in Basel, Switzerland. This presentation may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.</i>		
13:30 – 13:42	Overview of AA and PNH: From Pathophysiology to Practice	Beatrice Drexler (CH)
13:42 – 14:07	Best Practice in Action: Expert Perspectives on AA and PNH Care <i>Interactive case-based discussion</i>	Shinji Nakao (JP) Morag Griffin (UK)
14:07 – 14:15	Audience Q&A	All
14:15 – 15:30	<b>Session VII: PNH</b> <b>Chairs:</b> <i>Rodrigo Calado (BR) &amp; Austin Kulasekararaj (UK)</i>	
14:15 – 14:35	Therapeutic algorithm in 2025 for PNH	Morag Griffin (UK)
14:35 – 14:55	HSCT in PNH	Camilla Frieri (IT)
14:55 – 15:15	Future directions in PNH	Régis Peffault de la Tour (FR)
15:15 – 15:30	Discussion	
15:30 – 16:00	<b>Coffee Break</b>	
16:00 – 17:15	<b>Session VIII: The patients, the nurses and caregivers perspective</b> <b>Chairs:</b> <i>Britta Höchsmann (DE) &amp; Jens Panse (DE)</i>	
16:00 – 16:25	Deciphering fatigue in AA/PNH for future care	Pascale Burmester (DE)
16:25 – 16:50	Transition of AA patients	Kelly Hennessy (UK)
16:50 – 17:15	Infectious risk in AA patients	Flore Sicre de Fontbrune (FR)

## Preliminary Programme

Basel, Switzerland  
9-11 October 2025

**Saturday, 11 October 2025**

09:00 – 10:00	<b>Session IX: Deciphering acquired versus inherited BMFs in 2025</b> <b>Chairs:</b> <i>Maurizio Miano (IT) &amp; Alicia Rovó (CH)</i>	
09:00 – 09:20	From the paediatric perspective	Carlo Dufour (IT)
09:20 – 09:40	From the adults perspective	Simone Feurstein (DE)
09:40 – 10:00	New germline kids on the block in 2025	Marcin Wlodarski (DE)
10:00 – 11:00	<b>Session X: Long-term outcome</b> <b>Chairs:</b> <i>André Tichelli (CH) &amp; Simone Cesaro (IT)</i>	
10:00 – 10:20	Long term outcome in IST versus HCT	Beatrice Drexler (CH)
10:20 – 10:40	How to follow up on inherited BMF to detect “transformation”	Marcin Wlodarski (DE)
10:40 – 11:00	How to follow up on QoL in AA?	Jens Panse (DE)
11:00 – 11:30	<b>Coffee Break</b>	
11:30 – 12:30	<b>Session XI: Future Directions</b> <b>Chairs:</b> <i>Beatrice Drexler (CH) &amp; Anna Sureda (ES)</i>	
11:30 – 11:55	Finding the individual trigger in acquired AA	Jaroslawn Maciejewski (US)
11:55 – 12:20	New kids on the block (Ruxo, Tregs, ...)	Shreyans Gandhi (UK)
12:20 – 12:30	Closing remarks	